GT Biopharma GTBP 深 沪
已收盘 12-19 16:00:00 美东时间
0.7569
+0.022
+3.02%
华盛通- 最 高0.77
- 今 开0.76
- 成交量 239.43万股
- 最 低 0.712
- 昨 收 0.7347
- 总市值 805.05万
- 52周最高 3.85
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 0.54
- 委 比 64.31%
- 总股本 1063.61万
- 历史最高 591.99
- 量 比 1.26
- 振 幅 7.89%
- 历史最低 0.54
- 每 手 1
- 风险率 0.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has...
12-19 20:55
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift to...
12-11 23:17
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers GT Biopharma (NASDAQ:GTBP) shares moved upwards by 6.6% to $0.65 durin...
12-06 05:05
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia ...
12-05 01:20
Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
Shares of Quantum Computing Inc. (NASDAQ:QUBT) rose sharply in pre-market tradi...
11-17 17:42
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GT Biopharma announced updates on its Phase 1 trial for GTB-3650, targeting relapsed/refractory CD33+ hematologic malignancies, with enrollment ongoing and the next update expected in Q1 2026. The IND submission for GTB-5550, targeting B7H3+ solid tumors, is anticipated in late December 2025 or January 2026. The company reported a cash position of $2.6 million as of September 30, 2025, sufficient to fund operations into Q1 2026. R&D expenses decr...
11-14 14:00
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – MIT and Harvard scientists recently created...
10-17 21:50
Precision Oncology Approaches Drive $312B Market Transformation
USA News Group News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, Oct. 17, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development accelerates ...
10-17 21:00
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
USA News Group News Commentary – Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development is acc...
10-15 21:11
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares rose 113.4% to $3.99 during T...
10-09 20:07
